Commercial, Strategy, Ops

🇺🇸 San Francisco, California
$2K - $3K Annual
Posted 1 day ago
Expires December 20, 2026

About Axiom

Axiom is building the closed-loop scientific AI system required to replace animal testing and, over time, much of human safety testing. We start with pharma’s hardest drug development toxicology problems. Those problems define the proprietary human biological data we generate through Axiom’s Data Factory. We use that data to train scientific AI, partnering with leading AI labs to improve frontier models while building our own specialist agentic harness to deploy the improved frontier models back into pharma. Each deployment reveals the next capabilities to build, creating a compounding loop across data, models, and drug development. Today, liver toxicity is our proving ground. Axiom is already helping leading pharmaceutical companies understand toxicity, identify its mechanism, and design safer drugs. Over time, we will expand across the major organ systems and build the experimental and agentic system of record for translational drug development. Our goal is to dramatically reduce the risk of testing new molecules in humans, enabling high throughput evaluation of efficacy in humans.

What You Will Do

You will own the commercial strategy and operations.

You will:

- Work with the founders and team to map the people and phased progression strategy for every major account including top pharmaceuticals and AI research labs

- Own pilot operational execution and pilot-to-revenue conversion across Axiom’s commercial pipeline

- Partner closely with the CEO and technical leadership to turn customer excitement into durable enterprise adoption for companies ranging in size from $100B to over $1T

- Chart the course for major accounts going from 6 figures to 7 figures to 8 figures and beyond

- Build relationships across scientific, technical, business, legal, procurement, and executive teams

- Build and run a rigorous commercial operating system: pipeline management, forecasting, pricing, packaging, deal strategy, and expansion

- Act as the voic...